For biologics sponsors, true CDMO capacity depends on more than open slots—it requires the right technical capabilities, locations, and ability to adapt as a program evolves. Historically, biopharmaceutical supply chain disruption was treated as an isolated logistical or procurement problem. Today, supply chain disruptions present systemic risks that can impact clinical development timelines and threaten the continuous supply of therapies to patients.
Biopharmaceutical companies are now gauging the supply chain resilience of contract development and manufacturing organizations (CDMOs) when selecting partners. This requires a holistic view of supply networks, focusing on geographic concentration, material dependencies, future manufacturing capacity, and technical capability. A resilient CDMO network can help biopharma companies manage bottlenecks and pitfalls before they affect programs.
Onshoring and regionalization are two approaches to enhance supply resilience. Onshoring involves returning manufacturing to the domestic market, while regionalization distributes capabilities across multiple markets. Both strategies require careful assessment of supplier diversity and transfer readiness to ensure effective manufacturing continuity.
Capacity planning is challenging due to unpredictable demand for biologics. CDMOs must prepare for multiple outcomes and remain flexible as clinical programs progress. A resilient CDMO can adapt its operations to meet changing demands, ensuring that biopharma companies can respond effectively to uncertainties in the market.
Source: contractpharma.com · Image: MRF-D volunteers at a local food bank (6711212) by U.S. Marine Corps photo by Cpl. Colton Garrett, Public domain, via Wikimedia Commons
Start your 7-day trial and see what the database can do →
